Alnylam Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 2003
Revenue	1,828	1,037	844.29	492.85	219.75	74.91	89.91	47.16	41.1	50.56	Upgrade
Revenue Growth (YoY)	76.23%	22.88%	71.31%	124.28%	193.36%	-16.69%	90.66%	14.75%	-18.72%	7.20%	Upgrade
Cost of Revenue	310.41	168.82	140.14	78.05	25.06	1.8	0	0	0	0	Upgrade
Gross Profit	1,518	868.6	704.14	414.8	194.69	73.11	89.91	47.16	41.1	50.56	Upgrade
Selling, General & Admin	795.65	770.66	620.64	588.42	479.01	382.36	199.37	89.35	60.61	44.53	Upgrade
Research & Development	1,004	883.02	792.16	654.82	655.11	505.42	390.64	382.39	276.5	190.25	Upgrade
Other Operating Expenses	0	0	0	0	0	0	0	0	0	220.77	Upgrade
Operating Expenses	1,800	1,654	1,413	1,243	1,134	887.78	590	471.75	337.11	455.54	Upgrade
Operating Income	-282.18	-785.07	-708.65	-828.44	-939.43	-814.67	-500.09	-424.59	-296.01	-404.98	Upgrade
Interest Expense / Income	121.22	155.97	143.02	84.5	0	0	0	0	0	0	Upgrade
Other Expense / Income	30.12	185.95	0.47	-57.33	-54.18	-54	-9.21	-14.48	-5.94	-4.38	Upgrade
Pretax Income	-433.52	-1,126.99	-852.14	-855.6	-885.25	-760.67	-490.87	-410.11	-290.07	-400.6	Upgrade
Income Tax	6.73	4.16	0.68	2.68	0.86	0.82	0	0	0	-40.21	Upgrade
Net Income	-440.24	-1,131.16	-852.82	-858.28	-886.12	-761.5	-490.87	-410.11	-290.07	-360.4	Upgrade
Shares Outstanding (Basic)	125	122	118	115	109	101	91	86	84	74	Upgrade
Shares Outstanding (Diluted)	125	122	118	115	109	101	91	86	84	74	Upgrade
Shares Change	2.64%	2.73%	3.01%	5.24%	8.62%	11.08%	5.79%	1.91%	13.08%	20.68%	Upgrade
EPS (Basic)	-3.52	-9.30	-7.20	-7.46	-8.11	-7.57	-5.42	-4.79	-3.45	-4.85	Upgrade
EPS (Diluted)	-3.52	-9.30	-7.20	-7.46	-8.11	-7.57	-5.42	-4.79	-3.45	-4.85	Upgrade
Free Cash Flow	41.95	-613.33	-718.07	-685.32	-418.58	-689.5	-487	-372.26	-202.09	-174.6	Upgrade
Free Cash Flow Per Share	0.34	-5.04	-6.06	-5.96	-3.83	-6.86	-5.38	-4.35	-2.41	-2.35	Upgrade
Gross Margin	83.02%	83.73%	83.40%	84.16%	88.60%	97.59%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-15.43%	-75.68%	-83.93%	-168.09%	-427.50%	-1087.56%	-556.20%	-900.33%	-720.27%	-800.97%	Upgrade
Profit Margin	-24.08%	-109.04%	-101.01%	-174.15%	-403.24%	-1016.58%	-545.95%	-869.63%	-705.83%	-712.79%	Upgrade
Free Cash Flow Margin	2.29%	-59.12%	-85.05%	-139.05%	-190.48%	-920.47%	-541.64%	-789.37%	-491.74%	-345.33%	Upgrade
EBITDA	-215.27	-885.48	-619.43	-696.67	-830.89	-745.43	-478.98	-394.98	-271.02	-388.68	Upgrade
EBITDA Margin	-11.77%	-85.35%	-73.37%	-141.35%	-378.10%	-995.12%	-532.72%	-837.55%	-659.47%	-768.73%	Upgrade
Depreciation & Amortization	97.03	85.55	89.69	74.44	54.37	15.25	11.9	15.13	19.05	11.93	Upgrade
EBIT	-312.3	-971.03	-709.12	-771.1	-885.25	-760.67	-490.87	-410.11	-290.07	-400.6	Upgrade
EBIT Margin	-17.08%	-93.60%	-83.99%	-156.46%	-402.85%	-1015.48%	-545.95%	-869.63%	-705.83%	-792.32%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).